Item 8.01 Other Events.

On January 4, 2022, Gritstone bio, Inc. (the "Company" or "Gritstone") announced positive clinical results from the first cohort of its Phase 1 Study (CORAL-BOOST) evaluating a T cell-enhanced self-amplifying mRNA (samRNA) vaccine against COVID-19. A copy of the press release with the foregoing announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Spokespersons of Gritstone plan to present the information in the presentation slides attached hereto as Exhibit 99.2 at various upcoming investor and analyst meetings previously announced by the Company. A copy of the presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

Exhibit
  No.       Description

99.1          Press Release dated January 4, 2022

99.2          Presentation Slides January 2022

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses